Press releases
![](https://www.luzsana.com/wp-content/themes/Luzsana/images/news/luzsana-logo.png)
Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elevar Therapeutics
Read the press release >![](https://www.luzsana.com/wp-content/themes/Luzsana/images/news/luzsana-logo.png)